EVAMPLIX (BALSTILIMAB)
Dead / Abandoned — Abandoned — no statement of use filed (as of 01 May 2023)
What this means for you
This application is over — abandoned 01 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90836060
- Mark type
- Design + words
- Filed
- 19 Jul 2021
- Published for opposition
- 02 Aug 2022
- Abandoned
- 01 May 2023
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases
Owner
- Agenus Inc., Lexington, MA, US
- Agenus Inc., Lexington, MA, US
Prosecution history
- 01 May 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 01 May 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 27 Sept 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Aug 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Aug 2022 — PUBLISHED FOR OPPOSITION
- 13 Jul 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Jun 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Jun 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Jun 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Jun 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 30 Dec 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 30 Dec 2021 — NON-FINAL ACTION E-MAILED
- 30 Dec 2021 — NON-FINAL ACTION WRITTEN
- 30 Dec 2021 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 23 Nov 2021 — WITHDRAWN FROM PUB - OG REVIEW QUERY